Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

186.32USD
19 Sep 2017
Change (% chg)

$-0.15 (-0.08%)
Prev Close
$186.47
Open
$186.81
Day's High
$187.44
Day's Low
$185.81
Volume
2,020,529
Avg. Vol
3,007,569
52-wk High
$191.10
52-wk Low
$133.64

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $136,062.50
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.47

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

U.S. FDA approves biosimilar version of cancer drug Avastin

The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

Sep 14 2017

RPT-U.S. FDA approves biosimilar version of cancer drug Avastin

Sept 14 The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

Sep 14 2017

BRIEF-U.S. FDA approved Amgen's Mvasi as a biosimilar to Avastin

* U.S. FDA says approved Amgen's Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer

Sep 14 2017

BRIEF-UCB and Amgen announce detailed results from the phase 3 ARCH study

* ANNOUNCED ON MONDAY, TOGETHER WITH AMGEN , DETAILED RESULTS FROM THE PHASE 3 ARCH STUDY

Sep 12 2017

BRIEF-European Commission approves expanded use of Mimpara for the treatment of secondary hyperparathyroidism in children with end-stage renal disease on dialysis

* European commission approves expanded use of Mimpara (cinacalcet) for the treatment of secondary hyperparathyroidism in children with end-stage renal disease on dialysis

Aug 31 2017

BRIEF-Long-Term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma

* Long-Term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma

Aug 30 2017

BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® (carfilzomib) label

* FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® (carfilzomib) label

Aug 30 2017

BRIEF-Amgen Foundation expands Amgen Biotech experience

* Amgen Foundation expands the Amgen Biotech experience, bringing total program reach to 900,000 high school students by 2020 Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Amgen to present new data from the Repatha cardiovascular outcomes study

* Amgen to present new data from the Repatha cardiovascular outcomes study at ESC congress 2017 Source text for Eikon: Further company coverage:

Aug 21 2017

BRIEF-Amgen and Humana partner for improved health outcomes

* Amgen and Humana partner for improved health outcomes and efficiency Source text for Eikon: Further company coverage:

Aug 17 2017

Earnings vs. Estimates